Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
While there has been substantial progress and notable achievements in the use of adeno-associated virus (AAV) gene therapy vectors for treatment of rare diseases, setbacks related to vector toxicit...
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is known that immunogenicity of AAV and the incidence of immune-related adverse events increases with the vector dose [reviewed (63)].”
From Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood (2022) · cites this paper as [63]
In the citing paper
“At such high doses, AAV administration has resulted in a variety of toxic effects 53 .”
From AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain (2025) · cites this paper as [53]
Citations
Cites
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Engineering adeno-associated virus vectors for gene therapy
Li, C., & Samulski, R. J. (2020) · Nature Reviews Genetics · doi:10.1038/s41576-019-0205-4 · Cited by 1,175 · cited 3×
“remove antibody epitopes [26] or use of plasmapheresis”
BackgroundSelf-citationAn estimation of the number of cells in the human body
Bianconi, E., Piovesan, A., Facchin, F., Beraudi, A., Casadei, R., Frabetti, F., Vitale, L., Pelleri, M. C., Tassani, S., Piva, F., et al. (2013) · Annals of Human Biology · doi:10.3109/03014460.2013.807878 · Cited by 1,012 · cited 1×
“Estimated number of total cells, neurons, hepatocytes, and skeletal muscle fibers in the human body [36] and the number of full viral capsids in a 1E14 vg/kg dose of AAV for a 70 kg human.”
BackgroundEmerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881 · cited 1×
“Immunogenicity of AAV gene therapy is much more complex and nuanced than that for most protein biologic therapies, which are typically affected only by anti-drug antibodies (ADAs) [2,6].”
BackgroundHinderer, C., Katz, N., Buza, E. L., Dyer, C., Goode, T., Bell, P., Richman, L. K., & Wilson, J. M. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.015 · Cited by 814 · cited 1×
“The clinical significance of DRG toxicity is uncertain, although ataxia and tremors has been reported in some NHP, and ataxia and proprioceptive deficits have been reported in piglets receiving an intravenous vector dose of 2E14 vg/kg [17,22].”
BackgroundHemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558
Nguyen, G. N., Everett, J. K., Kafle, S., Roche, A. M., Raymond, H. E., Leiby, J., Wood, C., Assenmacher, C.-A., Merricks, E. P., Long, C. T., et al. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-0741-7 · Cited by 424 · cited 1×
“Pre-neoplastic hepatic lesions have also been reported in long-term canine studies [18].”
BackgroundVector design influences hepatic genotoxicity after adeno-associated virus gene therapy
Chandler, R. J., LaFave, M. C., Varshney, G. K., Trivedi, N. S., Carrillo-Carrasco, N., Senac, J. S., Wu, W., Hoffmann, V., Elkahloun, A. G., Burgess, S. M., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79213 · Cited by 403 · cited 2×
“HCC has been primarily associated with vector integration at high AAV doses in neonatal mice, particularly with vectors that employ a strong promoter that may result in transactivation of protooncogenes [15,16].”
Background
Research works printed but not linked: 2
- Philippidis A, 2021, Genet Eng Biotechnol News
- Mullard A, 2021, Nature, 20, 804
Cited by
Immunogenicity and toxicity of AAV gene therapy
Ertl, H. C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.975803 · Cited by 402
“Preventing induction of AAV neutralizing antibodies following gene transfer by either inhibiting B cell activation or by removing such antibodies from the circulation would permit repeated administration of lower doses of AAV vectors to replace the currently used bolus approach (85).”
BackgroundLethal immunotoxicity in high-dose systemic AAV therapy
Duan, D. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.015 · Cited by 240
Efficient prime editing in mouse brain, liver and heart with dual AAVs
Davis, J. R., Banskota, S., Levy, J. M., Newby, G. A., Wang, X., Anzalone, A. V., Nelson, A. T., Chen, P. J., Hennes, A. D., An, M., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01758-z · Cited by 227
Viral Vector-Based Gene Therapy
Li, X., Le, Y., Zhang, Z., Nian, X., Liu, B., & Yang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097736 · Cited by 200
AAV-based in vivo gene therapy for neurological disorders
Ling, Q., Herstine, J. A., Bradbury, A., & Gray, S. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00766-7 · Cited by 197
Metadata
- Authors
- Kishimoto, T. K., & Samulski, R. J.
- Affiliations
- Selecta Biosciences (United States) (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Kishimoto, Takashi Kei
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2022-04-03
- Volume
- 22
- Issue
- 9
- Pages
- 1067-1071
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W4225772001
- Cited by
- 152
- References
- 28
- Citations by year
- 2026: 29 · 2025: 25 · 2024: 48 · 2023: 39 · 2022: 11
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Expert Opinion on Biological Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Keywords
- adeno-associated virus, vector toxicity, rare diseases, gene therapy safety
- MeSH terms
- Dependovirus, Genetic Vectors, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’. https://app.cochat.ai/papers/10.1080/14712598.2022.2060737
- The paper
- Kishimoto, T. K., & Samulski, R. J. (2022). Addressing high dose AAV toxicity – ‘one and done’ or ‘slower and lower’. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2022.2060737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.